ARCHIVES

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

Construction Needs From NCI Said $40 Million Year For Four Years

June 9, 1978

Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer

January 31, 2003

New AIDs System For Classification Increase By 1% Cases Reported

August 1, 1986

Consortium Aims To Make Mice Whose Cancers Act Human.

January 7, 2000

Chemical Carcinogenesis

November 18, 1994

713 Nurses Pass Certification exam At ONS Congress

July 8, 1988